Related Experiment Video

Updated: Sep 3, 2025

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.6K

Small Interfering RNA in Colorectal Cancer Liver Metastasis Therapy

Junlin Xie1,2, Shubin Wang1,2

  • 1Department of Oncology, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute, 74573Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen, China.

Technology in Cancer Research & Treatment
|July 28, 2022
PubMed

Insights

Small interfering RNAs (siRNAs) offer a promising therapeutic approach to inhibit gene expression and treat colorectal cancer liver metastasis (CRLM). Delivery systems are being developed to overcome challenges in siRNA stability and uptake for effective CRLM treatment.

Area of Science:

  • Molecular Biology
  • Genetics
  • Oncology

Background:

  • Colorectal cancer (CRC) frequently metastasizes to the liver, significantly impacting patient survival.
  • Existing therapies for colorectal cancer liver metastasis (CRLM) require enhancement.
  • RNA interference (RNAi) using small interfering RNAs (siRNAs) presents a novel therapeutic avenue.

Purpose of the Study:

  • To explore the potential of siRNA therapy in blocking liver metastasis in colorectal cancer.
  • To discuss the application of siRNA technology in targeting metastasis-related signaling pathways in CRLM.
  • To highlight the challenges and advancements in siRNA delivery systems for CRLM treatment.

Main Methods:

  • Reviewing the mechanism of RNA interference (RNAi) mediated by siRNAs.
  • Identifying key metastasis-related signaling pathways in CRLM amenable to siRNA targeting.
  • Examining current and emerging siRNA delivery systems to improve stability and cellular uptake.

Main Results:

  • siRNAs demonstrate the ability to regulate gene expression by degrading specific messenger RNA (mRNA) molecules.
  • Targeting metastasis-related pathways with siRNAs shows potential for inhibiting CRLM progression.
  • Development of delivery systems aims to address limitations of siRNA therapeutics, such as poor serum stability and off-target effects.

Conclusions:

  • siRNA therapy holds significant promise as a future treatment strategy for colorectal cancer liver metastasis.
  • Overcoming delivery challenges is crucial for realizing the full therapeutic potential of siRNAs in CRLM.
  • Targeted siRNA intervention in metastasis-related pathways could revolutionize CRLM management.
Keywords:
RNA interferencegene therapy colorectal cancer liver metastasissiRNAtherapeutic targets

More Related Videos

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

6.5K
DNA Vector-based RNA Interference to Study Gene Function in Cancer13:10

DNA Vector-based RNA Interference to Study Gene Function in Cancer

Published on: June 4, 2012

20.7K

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.8K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
Small interfering RNAs (siRNA)02:30

Small interfering RNAs (siRNA)

3.6K
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.4K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K